Clinical Trials

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

142 enrolled

Nasopharangeal Cancer

NCT06281405 2026-01-27

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT06468280 2026-01-21

ROSETTE

84 enrolled

Stomach Neoplasms

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

40 enrolled

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04146298 2025-12-24

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

50 enrolled

Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

183 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

12 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06507371 2025-06-26

mRCAT-III

170 enrolled

Rectal Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

CNS

Neuroblastoma

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

156 enrolled

Colorectal Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

24 enrolled

Colorectal Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

46 enrolled

Locally Advanced Rectal Cancer

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT05555888 2025-01-15

TORCH-E

34 enrolled

Early Low Rectal Cancer

NCT06417892 2025-01-14

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Recruiting

60 enrolled

Stomach Neoplasms

NCT05972655 2025-01-09

mRCAT

32 enrolled

Low Rectal Cancer

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT06349044 2024-08-27

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Phase NA Recruiting

120 enrolled

Carcinoma, Hepatocellular

NCT06396637 2024-05-02

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

20 enrolled

Pancreatic Adenocarcinoma Metastatic

NCT06357598 2024-04-10

PILOT

Phase 4 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

39 enrolled

Nasopharyngeal Carcinoma

NCT06170710 2023-12-14

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

173 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06122493 2023-11-08

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

10 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

NCT05961761 2023-07-27

PROPANE

80 enrolled

Sarcoma

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

40 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

556 enrolled

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

218 enrolled